Do millionaires use credit cards? Yes, and so should you.

If you use a rewards credit card, you're more like a millionaire than you may think. Although most adults have credit cards, millionaires are even more likely to use them. According to the Federal Reserve, almost all adults with incomes over $100,000 have a credit card in their name.
But if millionaires are so wealthy, why do they rely on credit? Credit cards provide plenty of benefits, even for the super-wealthy. However, you don't need a seven-figure net worth to take advantage of those benefits.
Millionaires use credit cards thanks to the convenience and perks they provide. These are some of the key benefits of using a credit card — even for people who can easily afford any purchase in cash:
Millionaires earn valuable rewards by using credit cards, from paying for groceries to buying clothing. For example, some cash-back cards offer 5% back on certain purchases, or you can use a travel credit card to earn points or airline miles that can be redeemed for travel.
Consider a card like the Capital One Venture Rewards Credit Card. This credit card offers a base earning rate of 2x miles on all eligible purchases. If a millionaire makes $50,000 in purchases, that's 100,000 miles (equal to $1,000 toward travel). That's not a bad return for purchases they're already making.
In the case of average consumers, we don't have to spend like millionaires to earn lots of rewards. If you have upcoming large expenses, you can time paying for them with a new card and earn a credit card sign-up bonus. This can immediately boost your rewards bank without any need to overspend.
Millionaires use credit cards because many credit cards automatically give you added protection and coverage. For example, the Chase Sapphire Preferred® Card offers the following protections:
Auto rental collision damage waiver
Baggage delay insurance
Extended warranty protection
Lost luggage reimbursement
Purchase protection
Roadside dispatch
Travel accident insurance
Travel and emergency assistance services
Trip cancellation and interruption insurance
Trip delay reimbursement
Some cards, like the Ink Business Preferred® Credit Card and Wells Fargo Active Cash® Credit Card, offer cell phone protection.
It's one thing to make a lot of money, but it's another to hold on to that money in different ways with good money habits, such as protecting your purchases. And certain credit cards provide an easy way to make sure you have automatic protections in place on qualifying purchases.Despite their incomes, millionaires still face some of the same annoyances or stressors while traveling, such as long lines at the airport. By using a card like the Capital One Venture X Rewards Credit Card, they can make the experience less stressful by utilizing the following perks:
TSA PreCheck or Global Entry fee credits: You can receive up to a $120 credit for Global Entry or TSA PreCheck application fees.
Airport lounge access: Cardholders receive complimentary access to Priority Pass and Capital One Lounge locations.
Travel concierge: Credit card concierge services can assist you if you need help booking reservations or finding a good hotel. They can even help you secure event tickets, refer medical or legal services, and assist with other emergencies.One of the reasons why millionaires use credit cards rather than cash or debit is because of the protection against fraud they provide. In most cases, if a credit card is lost or stolen, your maximum liability for unauthorized purchases is $50.
By contrast — depending on how quickly you report the charges — you may be responsible for the entire amount of unauthorized transactions with a debit card.Tracking spending with cash can be difficult. Tax season can be especially challenging unless you keep diligent records and store your receipts.
Credit cards allow you to sync your accounts with your favorite budgeting or bookkeeping software. You can quickly view your records to see how you've historically spent money, trends in your spending habits, and even look up specific transactions from the past. These records can make finding your charitable donations, medical expenses, and other potential deductions easier at tax time.Credit cards are often much more convenient than cash or paper checks. You don't have to worry about stopping at an ATM to make a withdrawal with your debit card, and you can add your credit card to your phone to make contactless or mobile payments.Unique cards for wealthy people include the American Express Centurion Card (Amex Black Card) and J.P. Morgan Reserve Card. However, rich people use various types of credit cards that are generally available to anyone who qualifies, such as The Platinum Card® from American Express and Chase Sapphire Reserve®. Note that many popular travel cards typically require at least a good credit score.
Rich people have the money to pay off credit card debt and don't have to carry credit card balances, so they don't have to worry about high interest rates or annual fees. Rather, they can focus on the benefits of credit cards, like earning rewards to continue to build wealth, taking advantage of travel perks, and using card protections and insurance.
They get many of the same benefits that the average cardholder can get from credit card companies, including:
Opportunities to build credit
Rewards on eligible purchases
Card protections and insurance coverage
Travel perks, such as airport lounge access
Expense tracking
Convenient payment method
Editorial Disclosure: The information in this article has not been reviewed or approved by any advertiser. All opinions belong solely to Yahoo Finance and are not those of any other entity. The details on financial products, including card rates and fees, are accurate as of the publish date. All products or services are presented without warranty. Check the bank's website for the most current information. This site doesn't include all currently available offers. Credit score alone does not guarantee or imply approval for any financial product.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Miami Herald

22 minutes ago

• Miami Herald

Oil up, but stocks look to slide after U.S. attacks on Iran

The U.S. attack on Iranian nuclear facilities on Saturday changes the focus of what's ahead for the U.S. economy in the last full week of June. Because everyone is waiting to see what Iran will do, other than fire missiles on Israel. That's what happened late Saturday. Don't miss the move: Subscribe to TheStreet's free daily newsletter The three biggest questions a day later: How will energy and stock markets react?Does Iran still have enough enriched uranium to make and deploy a small nuclear weapon?Will Iran move to block the ships from passing from the Persian Gulf through the Strait of Hormuz into global shipping lanes? Outside geopolitics, economic events coming up include Federal Reserve Chairman Jerome Powell's testimony before Congress on Tuesday and an important inflation report. Related: Netflix analysts turn heads with stock price target updates The nuclear question is on the table because U.S. officials weren't sure Sunday if the attacks on facilities at Fordow, Natanz and Isfahan actually destroyed nuclear materials. Vice President J.D. Vance, in fact, suggested that Iran's nuclear stock pile is still intact. If that's the case, it's possible Iran could assemble a first-generation weapon. That would be as powerful as the bombs dropped on Hiroshima and Nagasaki in 1945, Robert Pape of the Chicago Project on Security and Threats told MSNBC's Alex Witt on Sunday. Not having this awful idea become reality depends on cooler heads prevailing. A key issue: If Iran is willing to discuss destroying or otherwise ceding control its nuclear development efforts. The Trump Administration is threatening more attacks if Iran rejects the demand. Blocking the Strait of Hormuz, through which 25% of the world's crude oil passes - headed mostly to China, India and Asia - will send global oil prices surging and, ultimately, will boost gasoline prices in the United States and elsewhere. Stocks and bonds also would slump. ChinaCrude oil futures in New York opened up nearly $3 a barrel, then fell back quickly. At 7:30 p.m. EDT, crude was was up $2.12 to $75.99. Brent crude, the global benchmark, jumped to as high as $81.40, then fell back to $79.20 per barrel, up $2.19 Crude oil settled at $73.84 a barrel on Friday, up 34 cents. or 1.2%, from Thursday and up 21.5% so far in June. AAA's daily report on gasoline prices put the U.S. average at $3.218 a gallon, down slightly from Saturday's $3.129. Stock index futures were lower in early trading Sunday with S&P 500 futures off 28 points to 5,990. Futures based on the Dow Jones Industrial Average were down just 184 points to 42,333. Nasdaq-100 futures had fallen 137 points to 21,710. Stocks overall were flat last week even as global tensions heated up. Some defense-oriented stocks slipped on Friday. Palantir Technologies (PLTR) was off 2% to $137.30. Lockheed Martin (LMT) , however, was up 0.4% to $470.56. Federal Reserve Chairman Jerome Powell, who is always verbally battered by President Trump, will testify before the Congress twice this week. The questions almost certainly focus on the Iran situation and its impact on the economy. He will also have to explain why the Fed is so stubborn about NOT cutting its key federal funds rate. The Fed decided last week to leave its federal funds rate at 4.25% to 4.5%. One Fed governor, Christopher Waller, who voted in support of holding rates steady, thinks a rate cut could come in July. Mary Daly, president of the Federal Reserve Bank of San Francisco, thinks the Fed will have better information by September. The federal funds rate mostly affects short-term rates. Bond yields influence rates on, say, home mortgages and auto loans. The 30-year mortgage rate was just under 7% on Friday. Powell's first appearance is before the House Financial Services Committee on Tuesday and the Senate Banking Committee on Wednesday. More Economic Analysis: Federal Reserve prepares strong message on long-term interest ratesMassive city workers union approves strikeAnalyst makes bold call on stocks, bonds, and gold The most important economic report this coming week is the Personal Consumption Expenditures Index (PCE), due Friday from the U.S. Bureau of Economic Analysis. This is the Federal Reserve's preferred inflation rate. The index for May is expected to show a 2.3% year-over-year index. The core index, stripping out food and energy, is expected to rise 2.6%, up slightly from April. The inflation rate is still the lowest since March 2021, Barrons says. Four reports come this week that will help clarify the condition of the housing market. Existing homes sales for May, due Monday from the National Association of Realtors. Most estimates are around 4.1 million units on a seasonally-adjusted annual basis, up From April's 4 million rate. S&P Case-Shiller Home Price Index, due Tuesday from Standard & Poor' sales, due Wednesday from the Commerce Department. Pending home sales, due Thursday from the National Association of Home Builders. S&P Global reports its flash purchasing manager index reports for June. These measure what manufacturing and services companies are actually buying. The Conference Board comes out with its monthly Consumer Confidence Index report for June Tuesday morning It may show a slight gain because the data were collected as stocks were rallying after April's stock-market slump. The University of Michigan offers its revised Consumer Sentiment Index report on Friday. Its early version suggested consumers were a touch less worried and cited the market rally. Related: Veteran fund manager who predicted April rally updates S&P 500 forecast The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

Business Insider

an hour ago

• Business Insider

Coterra Energy (CTRA) Receives a Buy from Wells Fargo

Wells Fargo analyst Roger Read maintained a Buy rating on Coterra Energy (CTRA – Research Report) on June 20 and set a price target of $31.00. The company's shares closed last Friday at $26.97. Confident Investing Starts Here: According to TipRanks, Read is a 3-star analyst with an average return of 1.7% and a 53.80% success rate. Read covers the Energy sector, focusing on stocks such as Valero Energy, EOG Resources, and Phillips 66. In addition to Wells Fargo, Coterra Energy also received a Buy from Piper Sandler's Mark Lear in a report issued on June 16. However, on June 9, Morgan Stanley maintained a Hold rating on Coterra Energy (NYSE: CTRA). Based on Coterra Energy's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $924 million and a net profit of $516 million. In comparison, last year the company earned a revenue of $1.37 billion and had a net profit of $352 million Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CTRA in relation to earlier this year. Last month, Stephen Bell, the EVP – Business Development of CTRA sold 100,000.00 shares for a total of $2,525,000.00.

Business Wire

5 hours ago

• Business Wire

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM). The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. 'The STELLAR-303 results, which showed a survival benefit with the combination of zanzalintinib and atezolizumab versus regorafenib across all randomized patients with previously treated metastatic colorectal cancer, marks an important first milestone for our zanzalintinib pivotal development program,' said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. 'We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.' Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference. About STELLAR-303 STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or regorafenib. The study includes patients with previously treated non-MSI-high metastatic CRC. The dual primary endpoints of the study are OS in the ITT population and in the NLM subgroup of patients. Presence of liver metastases at baseline for all enrolled patients was determined by investigator assessment. Secondary endpoints include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. More information about the trial is available at About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company's flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including colorectal cancer, kidney cancer, head and neck cancer and neuroendocrine tumors. Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials. About CRC CRC is the third most common cancer and the second leading cause of cancer-related deaths in the U.S. 1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025. 1 CRC is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent. 2 Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 16.2%. 2 The liver is the most common site for CRC metastasis. Liver metastases significantly impact survival, with a median five-year survival rate of less than 14% when treated with palliative chemotherapy. 3 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of the combination of zanzalintinib in combination with atezolizumab to improve overall survival in patients with metastatic CRC; Exelixis' plans to discuss the trial data from STELLAR-303 with regulatory authorities and to present detailed findings at an upcoming medical conference; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; Exelixis' dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis' ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group. ___________________________ 1 Key Statistics for Colorectal Cancer. ACS website. Available at: Accessed June 2025. 2 Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: Accessed June 2025. 3 Ros J, Salva F, Dopazo C, et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer. May 2023;128(10):1797-1806.